Roivant Sciences Ltd (NAS:ROIV)
$ 12.71 0.02 (0.16%) Market Cap: 9.25 Bil Enterprise Value: 3.92 Bil PE Ratio: 2.25 PB Ratio: 1.81 GF Score: 61/100

Roivant Sciences Ltd at Goldman Sachs CEOs Unscripted Conference Transcript

Jan 05, 2023 / 07:55PM GMT
Release Date Price: $8.14 (+7.67%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - Research Analyst

Great. Well, thanks for coming, Matt, and thanks for everyone who's joining us both in-person and on the web stream.

So maybe, Matt, just to start, could you please just provide a brief overview of what you view as the key programs that are going to shape the Roivant story as we think about 2023?

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Sure. And thanks, Corinne, for having me and thanks to the conference for having us. It's great to be here. So I appreciate it.

Yes. Look, 2023 is a pretty incredible year for us actually. So I'd say major catalysts across, let's say, 4 programs at Roivant. We have this anti-TL1A antibody RVT-3101 that we in-licensed from Pfizer just last month on which we put out top-line data from our induction study yesterday. So there's additional data coming from that program midyear, first half of the year from our [maintenance] study. We have atopic dermatitis data coming from our commercial tapinarof VTAMA cream for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot